KISQALI in combination with an AI, regardless of menopausal status1
AI, aromatase inhibitor; CDK, cyclin-dependent kinase.
References: 1. KISQALI [Summary of Product Characteristics]. Novartis Pharma AG; 2019. 2. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2019;19(7):904-915. 3. Ibrance [Summary of Product Characteristics]. Pfizer Inc: 2018. 4. Verzenios [Summary of Product Characteristics]. Eli Lilly and Company; 2018.